Inovio Pharmaceuticals Inc vs CarMax, Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while CarMax, Inc trades at $55.91 (market cap $7.93B). The key difference: CarMax, Inc is far larger — about 88.8× Inovio Pharmaceuticals Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | KMX | |
|---|---|---|
Market Cap | $89.27M | $7.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $63.53 |
52-Week Low | $1.05 | $30.88 |
Enterprise Value | $60.28M | $26.44B |
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →